Ipsen's Kayfanda® Receives EU Approval for Alagille Syndrome Treatment
Kayfanda® Receives Approval for Treatment in the EU Ipsen has made a noteworthy advancement in pediatric healthcare with the recent authorization of Kayfanda® (odevixibat) in the European Union (EU). This innovative treatment specifically addresses cholestatic pruritus, a painful symptom linked to Alagille Syndrome, a rare liver disorder that affects children. This...
Continue Reading